An interventional study of Stapokibart (CM310) and Placebo in Non-Allergic Rhinitis With Eosinophilia Syndrome, sponsored by Huazhong University of Science and Technology. Not yet recruiting at 11 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Huazhong University of Science and Technology · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if Stapokibart (CM310) works to treat Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES) in adults. It will also learn about the safety of CM310.
The main questions it aims to answer are:
Does drug CM310 relieve the symptoms of participants? What medical problems do participants have when injecting CM310? Researchers will compare CM310 to a placebo (a look-alike substance that contains no drug) to see if CM310 works to treat NARES.
Participants will:
Inject CM310 or a placebo every 2 weeks for 12 weeks, and follow up for another 8 weeks.
Visit the clinic once every 2 weeks for checkups and tests. Keep a diary of their symptoms every day.
The objective of this clinical trial is to evaluate the efficacy of Stapokibart (CM310) in alleviating nasal and ocular symptoms, as well as its safety profile, in adult patients with Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES) who have shown a suboptimal response to intranasal corticosteroids.
Adult NARES patients with an inadequate response to mometasone furoate nasal spray will be enrolled. While continuing treatment with intranasal mometasone furoate, patients will be randomized to receive either Stapokibart or a placebo. Over the 12-week treatment period and the subsequent 8-week follow-up period, the alleviation of nasal and ocular symptoms, the incidence of adverse events, and the results of safety assessments (such as physical examinations, electrocardiograms, complete blood counts, and blood biochemistry) will be evaluated. The final aim is to assess the efficacy and safety of Stapokibart in treating patients with NARES.
52 studies on the registry are indexed under Eosinophilia; 9 are open to participants now.
This study's planned enrollment of 90 is above the median of 48 across 32 interventional studies indexed under Eosinophilia.
Browse Eosinophilia studies →Huazhong University of Science and Technology is the lead sponsor of 248 studies on the registry; 62 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet all of the following criteria to be eligible for participation in this clinical trial.
Exclusion Criteria:
Subjects who meet any of the following criteria are not eligible to participate in this clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After enrollment, paticipants were given CM310 (with an initial dose of 600 mg followed by 300mg subcutaneous injection, once every two weeks) for 12 weeks. Follow up for another 8 weeks.Mometasone furoate was nasal sprayed daily during treatment
Biological: Stapokibart (CM310)
After enrollment, paticipants were given a placebo (subcutaneous injection, with the same dose as the experimental group, once every two weeks) for 12 weeks. Follow up for another 8 weeks. During the treatment period, mometasone furoate was sprayed nasal every day
Other: Placebo
Paticipants were given CM310 (with an initial dose of 600 mg followed by 300mg subcutaneous injection, once every two weeks) for 12 weeks. Follow up for another 8 weeks.During the treatment period, mometasone furoate was sprayed nasal every day
After enrollment, paticipants were given a placebo (subcutaneous injection, with the same dose as the experimental group, once every two weeks) for 12 weeks. Follow up for another 8 weeks. During the treatment period, mometasone furoate was sprayed nasal every day
The mean change from baseline in the Reflective Total Nasal Symptom Score (rTNSS) at Week 12.
The Reflective Total Nasal Symptom Score (rTNSS) assesses the severity of nasal symptoms over the past 12 hours and is evaluated in the morning (ante meridiem rTNSS, AMrTNSS) and evening (post meridiem rTNSS, PMrTNSS). The daily rTNSS is the average of AMrTNSS and PMrTNSS. rTNSS isa scoring scale ranging from 0 to 12, with higher scores indicating more severe symptoms.
Time frame: From enrollment to the end of treatment at 12 weeks
reflective Total Nasal Symptom Scores
Mean change from baseline in daily morning AM reflective Total Nasal Symptom Scores (AMrTNSS) during the treatment period; Mean change from baseline in daily evening PM reflective Total Nasal Symptom Scores (PMrTNSS) during the treatment period; rTNSS is the mean of AMrTNSS and PMrTNSS. The rTNSS, AMrTNSS, PMrTNSS are scoring scales ranging from 0 to 12, with higher scores indicating more severe symptoms
Time frame: From enrollment to the end of study at 20 weeks
Instant Total Nasal Symptom Score (iTNSS)
Mean change from baseline in the Instant Total Nasal Symptom Score (iTNSS) immediately prior to dosing during the treatment period; The iTNSS is a scoring scale ranging from 0 to 12, with higher scores indicating more severe symptoms
Time frame: From enrollment to the end of study at 20 weeks
reflective individual nasal symptom scores
Mean change from baseline in daily reflective individual nasal symptom scores (rhinorrhea, nasal congestion, nasal itching, sneezing) during the treatment period. Daily reflective individual nasal symptom scores are the means of daily daytime (AM) reflective individual nasal symptom scores and daily nighttime (PM) reflective individual nasal symptom scores. Each symptom score is a scale ranging from 0 to 3, with higher scores indicating more severe symptoms
Time frame: From enrollment to the end of study at 20 weeks
Reflective Total Ocular Symptom Score
Mean change from baseline in the daily morning ante meridiem rTOSS (AMrTOSS) during the treatment period should be recorded; and mean change from baseline in the daily evening post meridiem rTOSS (PMrTOSS) during the treatment period should be recored; Mean change from baseline in the daily Reflective Total Ocular Symptom Score (rTOSS) during the treatment period should be calculated. Daily rTOSS is the mean of AMrTOSS and daily PMrTOSS. The rTOSS, AMrTOSS, PMrTOSS are scoring scales ranging from 0 to 9, with higher scores indicating more severe symptoms
Time frame: From enrollment to the end of study at 20 weeks
Instant Total Ocular Symptom Score (iTOSS)
Mean change from baseline in the Instant Total Ocular Symptom Score (iTOSS) immediately prior to dosing during the treatment period. The rTOSS is a scoring scale ranging from 0 to 9, with higher scores indicating more severe symptoms
Time frame: From enrollment to the end of study at 20 weeks
reflective individual ocular symptom scores
Mean change from baseline in daily reflective individual ocular symptom scores (ocular itching, tearing, eye redness) during the treatment period. Daily reflective individual ocular symptom scores are means of daytime (AM) reflective individual ocular symptom scores and nighttime (PM) reflective individual ocular symptom scores. Each of reflective individual ocular symptom score is a scale ranging from 0 to 3, with higher scores indicating more severe symptoms.
Time frame: From enrollment to the end of study at 20 weeks
Assessment of patient quality of life using the Rhino-Conjunctivitis Quality of Life Questionnaire (RQLQ)
Assessment of patient quality of life using the Rhino-Conjunctivitis Quality of Life Questionnaire (RQLQ), including domains such as daily activities, sleep disturbance, practical problems, nasal symptoms, ocular symptoms, and emotional function, with calculation of the total score. The RQLQ is a scoring scale ranging from 0 to 168, with higher scores indicating a greater impact of symptoms on daily life.
Time frame: From enrollment to the end of study at 20 weeks
visual analogue scale of olfactory function
Evaluation of olfactory function using the visual analogue scale (VAS).The VAS is a scoring scale ranging from 0 to 10, with higher scores indicating more severe symptoms.
Time frame: From enrollment to the end of treatment at 12 weeks
Overall evaluation of treatment response
Overall evaluation of treatment response based on a 7-point categorical scale, where subjects rate the change in NARES symptoms at the end of the study as follows: significantly improved, moderately improved, mildly improved, no change, mildly worsened, moderately worsened, or significantly worsened.
Time frame: From enrollment to the end of the study at 20 weeks
Area Under the Curve (AUC) for the change from baseline in daily rTNSS during the treatment period.
Area Under the Curve (AUC) for the change from baseline in daily rTNSS during the treatment period.
Time frame: From enrollment to the end of treatment at 12 weeks
Number of days with no or mild symptoms during the treatment period.
For daily rTNSS and rTOSS, days with no or mild symptoms are defined as follows: No or mild nasal symptoms: each individual symptom score (rhinorrhea, nasal congestion, nasal itching, sneezing) ≤ 1. No or mild ocular symptoms: each individual symptom score (ocular itching, tearing, eye redness) ≤ 1.
Time frame: From enrollment to the end of treatment at 12 weeks
Peripheral Blood eosinophil
Peripheral Blood Parameters: Changes in eosinophil count will be recorded and Changes in eosinophil percentage will be calculated
Time frame: At day 1, day 85 and day 141
Peripheral Blood Cytokines and chemokines
Peripheral Blood Cytokines and chemokines will be detected: Interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17A, Tumor Necrosis Factor (TNF)-α, Interferon (IFN)-γ, Monocyte Chemoattractant Protein (MCP)-1, Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Eosinophil Cationic Protein (ECP). The levels of peripheral blood cytokines and chemokines will be represented in picogram/milligram or nanogram/milligram
Time frame: At day 1, day 85 and day 141
Peripheral Blood Immunoglobulins
Concentrations of specific and total Immunoglobulin (Ig) A, IgG4, IgG, IgE, and total IgM will be detected and represented in picogram/milligram or nanogram/milligram
Time frame: At day 1, day 85 and day 141
Nasal Secretion Neurotransmitters and Proteases
Nasal secretion neurotransmitters and proteases: Vasoactive Intestinal Polypeptide (VIP), Substance P, histamine, 5-Hydroxytryptamine (5-HT), tryptase will be detected.The levels of neurotransmitters and proteases will be represented in picogram/milligram or nanogram/milligram
Time frame: At day 1, day 85 and day 141
Nasal Secretion Cytokines and chemokines
Nasal Secretion cytokines and chemokines:IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17A, TNF-α, IFN-γ, MCP-1, G-CSF, GM-CSF, ECP, Charcot-Leyden Crystal (CLC), eotaxin-1, eotaxin-2 will be detected. The levels of nasal secretion cytokines and chemokines will be represented in picogram/milligram or nanogram/milligram
Time frame: At day 1, day 85 and day 141
Nasal Brush Cytology
Nasal brush cytology: changes in eosinophil count will be recorded and changes in eosinophil percentage will be calculated.
Time frame: At day 1, day 85 and day 141
mRNA expression levels of genes of nasal brush cells
The mRNA expression levels of CLC, Arachidonate 15-Lipoxygenase (ALOX15), ALOX5, Cyclooxygenase (COX), Transient Receptor Potential Melastatin 8 (TRPM8), Transient Receptor Potential Vanilloid subfamily 1 (TRPV1), TRPV4, and Transient Receptor Potential Ankyrin subtype 1 protein (TRPA1) will be detected.
Time frame: At day 1, day 85 and day 141
Safety Endpoints
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) will be reported
Time frame: From enrollment to the end of study at 20 weeks
Safty endpoint
Abnormalities in physical examinations
Time frame: From enrollment to the end of study at 20 weeks
Safty endpoint
Abnormalities in 12-lead electrocardiogram (ECG) will be reported
Time frame: From enrollment to the end of study at 20 weeks
Safty endpoint
Abnormalities in complete blood count, blood chemistry, urinalysis will be reported.
Time frame: From enrollment to the end of study at 20 weeks
Plan to share: Yes — IPD used in the results publication
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 6 months and ending 3 years after the publication of results
Access criteria: The study protocol, statistical analysis plan, and study results from this research will be available on ClinicalTrials.gov and in journals where the primary results are published. If additional data is required by other researchers, they may contact the corresponding author to request access to the data after the publication of the primary study findings.
No publications or documents are linked to this record.
Start is estimated for Nov 2025; primary completion for Dec 2026, 13 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stapokibart
Huazhong University of Science and Technology →